Home
Clinical Trials
Combination Chemotherapy in T...

Combination Chemotherapy in Treating Women With Resected Breast Cancer

Last Updated: 2009-02-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2001-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them after surgery may kill any tumor cells remaining after surgery. It is not yet known which combination chemotherapy regimen is more effective in treating resected stage I or stage II breast cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of different combination chemotherapy regimens in treating women who have resected stage I or stage II breast cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Combination Chemotherapy Following Surgery in Treating Women With Early Stage Breast Cancer

NCT00003012

Breast Cancer

COMPLETED PHASE3

Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer

NCT00003680

Breast Cancer

UNKNOWN PHASE3

Combination Chemotherapy in Treating Women With Breast Cancer

NCT00047099

Breast Cancer

COMPLETED PHASE3

Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By Surgery

NCT00301925

Breast Cancer

UNKNOWN PHASE3

Combination Chemotherapy in Treating Women With Stage III Breast Cancer

NCT00002696

Breast Cancer

SUSPENDED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

* Compare the disease-free and overall survival of women with completely resected stage I or II breast cancer adjuvantly treated with fluorouracil, epirubicin, and cyclophosphamide (FEC) or epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil (EPI-CMF) versus FEC followed by sequential docetaxel.
* Compare the acute toxicity of these regimens in these patients.
* Compare the quality of life of patients treated with these regimens.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center, estrogen receptor status (positive vs negative), and nodal status. Within 8 weeks after definitive surgery, patients are randomized to 1 of 2 treatment arms.

* Arm I: Patients are assigned to 1 of 2 standard adjuvant chemotherapy regimens.

* Regimen A: Patients receive fluorouracil, epirubicin, and cyclophosphamide (FEC) IV on day 1. Treatment repeats every 3 weeks for 8 courses.
* Regimen B: Patients receive epirubicin IV on day 1. Treatment repeats every 3 weeks for 4 courses. Patients then receive cyclophosphamide orally on days 1-14 or IV on days 1 and 8 and methotrexate IV and fluorouracil IV on days 1 and 8 (CMF). Treatment with CMF repeats every 4 weeks for 4 courses.
* Arm II: Patients receive 4 courses of adjuvant chemotherapy with FEC as in arm I, regimen A. Patients then receive sequential docetaxel IV over 1 hour once every 3 weeks for 4 courses.

Beginning within 4 weeks after completion of adjuvant chemotherapy, patients who are not concurrently enrolled in the Standardization of Breast Radiotherapy (START) trial receive localized radiotherapy once daily, 5 days a week, for 3-5 weeks, according to local practice.

Beginning within 4 weeks after completion of adjuvant chemotherapy, patients who are estrogen receptor and/or progesterone receptor positive receive oral tamoxifen once daily for at least 5 years.

Quality of life is assessed at baseline, before course 5, at 3-4 weeks after course 8, and then at 9, 12, 18, and 24 months after initiation of adjuvant chemotherapy.

Patients are followed every 3 months for 2 years and then every 6 months thereafter.

Peer Reviewed and Funded or Endorsed by Cancer Research UK

PROJECTED ACCRUAL: A total of 3,340 patients (1,670 per treatment arm) will be accrued for this study within 2 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Primary Study Purpose

TREATMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CMF regimen

Intervention Type DRUG

cyclophosphamide

Intervention Type DRUG

docetaxel

Intervention Type DRUG

epirubicin hydrochloride

Intervention Type DRUG

fluorouracil

Intervention Type DRUG

methotrexate

Intervention Type DRUG

tamoxifen citrate

Intervention Type DRUG

adjuvant therapy

Intervention Type PROCEDURE

radiation therapy

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

DISEASE CHARACTERISTICS:

* Histologically confirmed completely resected, invasive breast cancer for which adjuvant chemotherapy is indicated
* No clinical or radiological evidence of locoregional or metastatic disease
* No locally advanced tumors at diagnosis, indicated by any of the following:

* Fixed tumors
* Peau d'orange skin changes
* Skin ulceration
* Inflammatory changes (T4 or T3b, N2 disease)
* No male breast cancer
* No prior invasive breast cancer or bilateral breast cancer
* Prior ductal carcinoma in situ or lobular carcinoma in situ is allowed
* Must begin study chemotherapy within 8 weeks after definitive surgery
* Hormone receptor status:

* Estrogen receptor and progesterone receptor status known

PATIENT CHARACTERISTICS:

Age:

* Over 18

Sex:

* Female

Menopausal status:

* Not specified

Performance status:

* WHO 0-1

Life expectancy:

* At least 2 years

Hematopoietic:

* WBC at least 3,000/mm\^3
* Platelet count at least 100,000/mm\^3
* Hemoglobin at least 9 g/dL

Hepatic:

* Bilirubin normal
* AST no greater than 1.5 times normal
* Alkaline phosphatase no greater than 1.5 times normal

Renal:

* Creatinine no greater than 1.5 times normal

Cardiovascular:

* No myocardial infarction within the past 6 months
* No congestive heart failure

Other:

* Not pregnant or nursing
* Fertile patients must use effective contraception
* No other invasive malignancy within the past 10 years except surgically cured nonmelanoma skin cancer or carcinoma in situ of the cervix
* No other serious medical illness that would limit life expectancy
* No psychiatric condition that would preclude informed consent
* No active uncontrolled bacterial, viral, or fungal infection

PRIOR CONCURRENT THERAPY:

Biologic therapy:

* No prior biologic therapy

Chemotherapy:

* See Disease Characteristics
* No prior cytotoxic chemotherapy

Endocrine therapy:

* No concurrent hormonal therapy (e.g., tamoxifen) during study chemotherapy
* No concurrent hormone replacement therapy

Radiotherapy:

* No prior radiotherapy

Surgery:

* See Disease Characteristics

Other:

* At least 4 weeks since any prior unlicensed drugs
* No other concurrent experimental drugs

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jane Banerji

Role: STUDY_CHAIR

Institute of Cancer Research, United Kingdom

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

U.Z. Gasthuisberg

Leuven, , Belgium

Site Status

North Devon District Hospital

Barnstaple, England, United Kingdom

Site Status

Royal United Hospital

Bath, England, United Kingdom

Site Status

Queen Elizabeth Hospital at University of Birmingham

Birmingham, England, United Kingdom

Site Status

City Hospital - Birmingham

Birmingham, England, United Kingdom

Site Status

Blackpool Victoria Hospital

Blackpool, England, United Kingdom

Site Status

Pilgrim Hospital

Boston, England, United Kingdom

Site Status

Bradford Hospitals NHS Trust

Bradford, England, United Kingdom

Site Status

Royal Sussex County Hospital

Brighton, England, United Kingdom

Site Status

Bristol Haematology and Oncology Centre

Bristol, England, United Kingdom

Site Status

West Suffolk Hospital

Bury St Edmunds, England, United Kingdom

Site Status

Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust

Cambridge, England, United Kingdom

Site Status

Broomfield Hospital

Chelmsford, Essex, England, United Kingdom

Site Status

Cheltenham General Hospital

Cheltenham, England, United Kingdom

Site Status

Essex County Hospital

Colchester, England, United Kingdom

Site Status

Walsgrave Hospital

Coventry, England, United Kingdom

Site Status

Derbyshire Royal Infirmary

Derby, England, United Kingdom

Site Status

Royal Devon and Exeter Hospital

Exeter, England, United Kingdom

Site Status

Diana Princess of Wales Hospital

Grimsby, England, United Kingdom

Site Status

St. Luke's Cancer Centre at Royal Surrey County Hospital

Guildford, England, United Kingdom

Site Status

Royal Free and University College Medical School

Hampstead, London, England, United Kingdom

Site Status

Huddersfield Royal Infirmary

Huddersfield, West Yorks, England, United Kingdom

Site Status

Princess Royal Hospital

Hull, England, United Kingdom

Site Status

Ipswich Hospital NHS Trust

Ipswich, England, United Kingdom

Site Status

Queen Elizabeth Hospital

Kings Lynn, England, United Kingdom

Site Status

Cookridge Hospital at Leeds Teaching Hospital NHS Trust

Leeds, England, United Kingdom

Site Status

Leeds Cancer Centre at St. James's University Hospital

Leeds, England, United Kingdom

Site Status